Alopecia areata: A clinical overview

Postgraduate Medicine

Volumn 107, Issue 7, 2000, Pages 81-90

  Bertolino, Arthur P ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

1 CHLORO 2,4 DINITROBENZENE; CYCLOSPORIN; DITHRANOL; METHOXSALEN; MINOXIDIL; TRIAMCINOLONE; TRIOXYSALEN;

ALOPECIA AREATA; AUTOIMMUNE DISEASE; CLINICAL FEATURE; CONFERENCE PAPER; CORTICOSTEROID THERAPY; EPIDEMIOLOGICAL DATA; HAIR LOSS; PUVA; SKIN BIOPSY; SUPPORT GROUP; T LYMPHOCYTE; TREATMENT PLANNING;

EID: 0033935078     PISSN: 00325481     EISSN: None     Source Type: Journal    
DOI: 10.3810/pgm.2000.06.1111     Document Type: Conference Paper

References (22)

1. Simpson NB. Alopecia areata. In: Rook A, Dawber R, eds. Diseases of the hair and scalp. 2d ed. Boston: Blackwell Scientific, 1991:296-333
2. Safavi K. Prevalence of alopecia areata in the First National Health and Nutrition Examination Survey.(Letter) Arch Dermatol 1992;128(5):702
3. Safavi KH, Muller SA, Suman VJ, et al. Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin Proc 1995;70(7):628-33
4. McDonagh AJG, Messenger AG. The pathogenesis of alopecia areata. Dermatol Clin 1996;14(4):661-70
5. Colombe BW, Price VH, Khoury EL, et al. HLA class II alleles in long-standing alopecia totalis/alopecia universalis and long-standing patchy alopecia areata differentiate these two clinical groups. J Invest Dermatol 1995;104(5 Suppl):4-5S
6. Duvic M, Welsh EA, Jackow C, et al. Analysis of HLA-D locus allelles in alopecia areata patients and families. J Invest Dermatol 1995;104(5 Suppl):5-6S
7. Perret C, Brocker EB, Wiesner-Menzel L, et al. In situ demonstration of T cells in alopecia areata. Arch Dermatol Res 1982; 273(1-2):155-8
8. Gilhar A, Ullmann Y, Berkutzki T, et al. Autoimmune hair loss (alopecia areata) transferred by T lymphocytes to human scalp ex-plants on SCID mice, J Clin Invest 1998;101(1):62-7
9. Messenger AG, Bleehen SS. Alopecia areata: light and electron microscopic pathology of the regrowing white hair. Br J Dermatol 1984;110(2):155-62
10. Dillaha CJ, Rothman S. Therapeutic experiments in alopecia areata with orally administered cortisone. JAMA 1952;150:546-50
11. Kern F, Hoffman WH, Hambrick GW Jr, et al. Alopecia areata: immunologic studies and treatment with prednisone. Arch Dermatol 1973;107(3):407-12
12. Fiedler VC, Wendrow A, Szpunar GJ, et al. Treatment-resistant alopecia areata: response to combination therapy with minoxidil plus anthralin. Arch Dermatol 1990;126(6):756-9
13. Fiedler VC, Alopecia areata: a review of therapy, efficacy, safety, and mechanism. Arch Dermatol 1992;128(11):1519-29
14. Fiedler-Weiss VC, Buys CM. Evaluation of anthralin in the treatment of alopecia areata. Arch Dermatol 1987;123(11):1491-3
15. Rosenberg EW, Drake L. In: Discussion of Dunaway DA. Alopecia areata. Arch Dermatol 1976;112:256
16. Summer KH, Goggelmann W. 1-chloro-2,4-dinitrobenzene depletes glutathione in rat skin and is mutagenic in Salmonella cyphimurium. Mutat Res 1980;77(1):91-3
17. Happle R, Buchner U, Kalvaran KJ, et al. Contact allergy as a therapeutic tool for alopecia areata: application of squaric acid dihutylester. Arch Dermatol Res 1979;264:101-2
18. Happle R, Hausen BM, Wiesner-Menzel L. Diphencyprone in the treatment of alopecia areata. Acta Derm Venereol 1983;63(1): 49-52
19. Gupta AK, Ellis CN, Cooper KD, et al. Oral cyclosporine for the treatment of alopecia areata: a clinical and immunohistochemical analysis. J Am Acad Dermatol 1990;22(2 Pt 1):242-50
20. de Prost Y, Teillac D, Paquez F, et al. Placebo-controlled trial of topical cyclosporin in severe alopecia areata. (Letter) Lancet 1986;2(8510):803-4
21. Claudy AL, Gagnaire D. PUVA treatment of alopecia areata. Arch Dermatol 1983;119(12):975-8
22. Austin LM, Ozawa M, Kikuchi T, et al. The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol 1999; 113(5):752-9